VGLL2

VGLL2 is a transcriptional cofactor that partners with TEAD family transcription factors to regulate skeletal muscle fiber-type specification, mitochondrial oxidative capacity, and craniofacial development. It binds TEAD1 and TEAD4 through a conserved TONDU domain and an additional Ω-loop structural element, and forms complexes with MEF2c and NFATc1 in skeletal muscle; calcium signaling promotes its nuclear translocation and activation of TEAD-dependent transcription of slow-fiber genes including MYH7, while Vgll2-null mice exhibit a shift toward fast-twitch fibers and reduced oxidative metabolism, and transgenic overexpression enhances mitochondrial content, respiration, and exercise endurance (PMID:28769032, PMID:30724341, PMID:33060790, PMID:39286968). In zebrafish, vgll2a functions non-cell-autonomously in pharyngeal endoderm to support neural crest cell survival and craniofacial cartilage morphogenesis downstream of FGF and retinoic acid signaling (PMID:21741961). In oncogenic contexts, the VGLL2-NCOA2 fusion protein activates TEAD-dependent transcription independently of YAP/TAZ by recruiting histone acetyltransferase EP300, drives sarcomagenesis through reactivation of developmental programs including the GTPase ARF6, and is therapeutically targetable by EP300 small-molecule inhibition (PMID:36656711, PMID:40338073).

1. 2007 Medium

   Identifying VGLL2 as a highly expressed neonatal hypothalamic transcript that is absent in mature animals raised the question of whether it functions in developmental transcriptional programs beyond muscle.

   Evidence Gene expression profiling and real-time PCR in postnatal mouse ventromedial hypothalamus with zebrafish knockdown confirmation

   PMID:18077674

   Open questions at the time

   • No mechanistic target or binding partner identified in hypothalamic context
   • Functional consequence of hypothalamic Vgll2 loss not characterized beyond expression loss
2. 2011 High

   Demonstrating that zebrafish vgll2a is required non-cell-autonomously for neural crest survival and craniofacial cartilage formation established that VGLL2 functions in developmental signaling beyond muscle, regulated by FGF and retinoic acid pathways.

   Evidence Morpholino knockdown in zebrafish with TUNEL assay, Alcian blue staining, in situ hybridization, and FGF/RA pathway perturbation

   PMID:21741961

   Open questions at the time

   • Transcriptional targets of Vgll2 in pharyngeal endoderm not identified
   • Whether TEAD is the relevant partner in craniofacial context is untested
   • Mammalian craniofacial phenotype not examined
3. 2017 High

   Establishing that VGLL2 physically interacts with TEAD1/4 and that its loss shifts skeletal muscle toward fast-twitch fibers with downregulation of MYH7 and miR-208b defined the VGLL2-TEAD axis as a core regulator of slow muscle fiber identity.

   Evidence Co-immunoprecipitation with TEAD1/4, Vgll2 knockout mouse phenotyping with fiber-type quantification and qPCR

   PMID:28769032

   Open questions at the time

   • Structural basis of VGLL2-TEAD interaction not yet resolved
   • Whether VGLL2 directly activates MYH7 promoter or acts indirectly through miR-208b/Sox6 axis unclear
4. 2019 High

   Showing that calcium signaling promotes VGLL2 nuclear translocation and that VGLL2 forms complexes with MEF2c and NFATc1 in addition to TEAD1 during chronic overload revealed the signal-dependent activation mechanism coupling muscle use to slow-fiber gene programming.

   Evidence Synergist ablation in Vgll2-deficient mice, co-IP, MYH7 promoter luciferase reporter, calcium ionophore treatment with nuclear fractionation

   PMID:30724341

   Open questions at the time

   • Calcium-dependent kinase or phosphorylation event controlling nuclear import not identified
   • Relative contribution of TEAD versus MEF2c versus NFATc1 to VGLL2-dependent transcription not dissected
5. 2020 High

   Resolving that VGLL2 uses both a TONDU domain and an Ω-loop to bind TEAD — unlike VGLL1/3 which use only the TONDU domain — provided a structural explanation for differential TEAD engagement among VGLL paralogs.

   Evidence Structural and biochemical analysis of TEAD-binding domains

   PMID:33060790

   Open questions at the time

   • Full co-crystal structure of VGLL2-TEAD complex not available
   • Functional consequence of Ω-loop loss on muscle fiber-type phenotype not tested in vivo
6. 2023 High

   Demonstrating that the VGLL2-NCOA2 fusion is sufficient to generate mesenchymal tumors with immature skeletal muscle features and that ARF6 is a critical downstream effector established the oncogenic mechanism of this fusion and identified a therapeutic vulnerability.

   Evidence Zebrafish transgenic and mouse allograft tumor models, ARF6 knockout epistasis in cell culture, RNA-seq with patient sample validation

   PMID:36656711

   Open questions at the time

   • How ARF6 mechanistically promotes transformation downstream of VGLL2-NCOA2 not resolved
   • Whether wild-type VGLL2 has any role in ARF6 regulation unknown
7. 2024 High

   Transgenic overexpression of VGLL2 demonstrating enhanced mitochondrial DNA content, oxidative phosphorylation complex abundance, maximal respiration, and exercise endurance established VGLL2 as an integrative regulator coupling fiber-type identity with mitochondrial bioenergetics.

   Evidence Vgll2 transgenic overexpression mouse with fiber-type quantification, mitochondrial DNA quantification, oxygen consumption measurement in isolated fibers, and exercise testing

   PMID:39286968

   Open questions at the time

   • Direct transcriptional targets driving mitochondrial biogenesis not identified
   • Whether mitochondrial effects require TEAD or proceed through MEF2c/NFATc1 not determined
8. 2025 High

   Identifying EP300 recruitment as the mechanism by which VGLL2-NCOA2 activates TEAD-dependent transcription independently of YAP/TAZ, and showing that EP300 inhibition suppresses fusion-driven transformation, revealed the epigenetic basis of oncogenic VGLL2 fusion activity and a druggable target.

   Evidence Luciferase reporter assays, Co-IP for EP300, small-molecule EP300 inhibitor treatment in vitro and in vivo mouse models

   PMID:40338073

   Open questions at the time

   • Whether EP300 recruitment is relevant to wild-type VGLL2 transcriptional activity unknown
   • Genome-wide EP300 binding sites specific to VGLL2-NCOA2 versus TEAD1-NCOA2 not distinguished
   • Clinical efficacy of EP300 inhibition in VGLL2-NCOA2 sarcomas not tested

• The mechanism by which calcium signaling controls VGLL2 nuclear import, the identity of direct VGLL2-TEAD transcriptional targets genome-wide in muscle, and whether wild-type VGLL2 recruits EP300 or other coactivators remain unresolved.
• No phosphoproteomics or kinase identification for calcium-dependent VGLL2 nuclear translocation
• No ChIP-seq for VGLL2 in normal skeletal muscle
• Role of VGLL2 in human craniofacial or hypothalamic development not established